Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
T-024
A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan
Favorite
M-135
A Bayesian disease progression model for Major Depressive Disorder
Favorite
T-131
A Bayesian Model-based CTS Tool to Optimize Clinical Trial Design in Duchenne Muscular Dystrophy
Favorite
T-078
A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology
Favorite
M-061
A clinical trial simulator tool for a randomized delayed start trial in Parkinson’s disease
Favorite
T-084
A COMBINED EX VIVO AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC APPROACH TO INCORPORATE DRUG-DRUG INTERACTIONS FOR DOSING DURING CONTINUOUS RENAL REPLACEMENT THERAPY
Favorite
T-088
A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Favorite
T-116
A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
Favorite
T-071
A Framework for Evaluating Predictive Models Using Synthetic Image Covariates and Longitudinal Data
Favorite
T-117
A High-Dose Methotrexate Dashboard: Integrating MTXPK.org into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients with Malignant Conditions
Favorite
T-013
A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies
Favorite
M-002
A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials
Favorite
M-126
A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
Favorite
T-079
A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.
Favorite
M-089
A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK
Favorite
M-134
A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor
Favorite
M-030
A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease
Favorite
T-046
A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
Favorite
W-138
A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations
Favorite
T-001
A Model-based Pharmacokinetic Simulation Tool to Aid Dose Selection of Antisense Oligonucleotides Administered Intrathecally in Pediatrics
Favorite
T-103
A model-based simulation workflow enables automated and accurate generation of clinical pharmacology summary statistics, a workflow and case-study.
Favorite
M-106
A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
Favorite
T-056
A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
Favorite
T-011
A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Favorite
T-018
A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development
Favorite
M-090
A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival
Favorite
T-066
A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples
Favorite
T-036
A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Favorite
T-070
A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
Favorite
T-005
A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
Favorite
M-039
A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome
Favorite
M-057
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model
Favorite
T-062
A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics
Favorite
T-080
A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
Favorite
W-009
A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™️) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population
Favorite
M-137
A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Favorite
T-129
A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis
Favorite
T-101
A QSP model of atopic dermatitis to accelerate the clinical translation of novel combination therapies
Favorite
M-025
A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
Favorite
T-122
A Quantitative Systems Pharmacology Approach to Understand the Variability of Patient Response to T-cell Bi-specifics in Hematological Malignancies
Favorite
M-110
A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis
Favorite
T-010
A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
Favorite
M-100
A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding
Favorite
T-015
A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies
Favorite
T-067
A quantitative systems pharmacology-physiologically based pharmacokinetic model-guided antibiotics regimen design for the treatment of sepsis and septic shock patients
Favorite
T-050
A review of OSP suite PBBM capabilities: looking ahead
Favorite
M-073
A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation
Favorite
M-017
A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
Favorite
M-064
A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users
Favorite
T-026
A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Favorite
M-072
A shared pool modeling approach to describe antibody-mediated cell-cell interactions
Favorite
M-011
A Survey of Model Informed Approaches in Neuroscience Drug Development
Favorite
M-028
A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets
Favorite
M-014
A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model
Favorite
M-136
A time-to-event model for Bronchopulmonary dysplasia based on real-world data
Favorite
T-033
A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics
Favorite
M-068
A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
Favorite
M-056
A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy
Favorite
T-044
A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis
Favorite
M-032
A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Favorite
M-008
A within-host dynamic model of Bordetella pertussis to support vaccine development
Favorite
M-052
Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin
Favorite
T-099
Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Favorite
M-130
Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches
Favorite
W-033
Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options
Favorite
T-104
Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists
Favorite
M-099
Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
Favorite
M-079
Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
Favorite
T-043
Advancing Drug Development through Enhanced Exposure-Response Analysis: The R-Shiny App ERpmx
Favorite
T-063
Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development
Favorite
M-109
Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis
Favorite
T-060
AI-Driven Innovative Platform in Quantitative Pharmacology: Literature Insights and Automated Model Construction
Favorite
M-006
An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
Favorite
T-068
An integrated model of catabolic clearance mechanisms driving exposure-response confounding for immunotherapies in cancer: interactions between mAb drugs, Fc receptors, and endogenous serum proteins
Favorite
W-077
An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite
Favorite
T-029
An R-based workflow for clinical trial simulation tool with application in type 1 diabetes studies
Favorite
T-048
App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
Favorite
T-017
Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
Favorite
W-006
Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Favorite
T-112
Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials
Favorite
T-081
Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
Favorite
T-128
Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
Favorite
T-083
Application of quantitative systems pharmacology modeling in reverse translation
Favorite
T-115
Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models
Favorite
M-116
Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data
Favorite
M-083
Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework
Favorite
T-120
Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
Favorite
T-069
Assessment of Disease Similarity among Different Racial and/or Ethnic Groups in Oncology: ABC Framework
Favorite
M-026
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
Favorite
M-097
Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation
Favorite
M-129
Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach
Favorite
B
M-033
babelmixr2 and PopED: Quick Conversion of NONMEM, Monolix and nlmixr2/rxode2 Models to PopED Optimal Design Analysis
Favorite
T-100
Beyond Subcutaneous Dosing: Efficiency of liver-targeting siRNAs dosed via alternates routes and formulations.
Favorite
T-125
Beyond the Michaelis-Menten: Evaluation of Novel IVIVE Approach for Predicting In Vivo Intrinsic Clearance from Hepatocyte Assays
Favorite
M-029
Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction
Favorite
T-041
Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa
Favorite
T-073
Bispecific T-cell engagers and cytokine release syndrome: Modeling molecule, indication and patient-specific aspects
Favorite
T-016
Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
Favorite
T-049
Building Automated Pharmacometrics Analysis Workflows in R with NMsim
Favorite
C
M-101
Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach
Favorite
W-134
Causal directed acyclic graph (DAG) application in exposure-response analyses
Favorite
W-063
Cell-line Specific Network Modeling to Assess Differential Signal Transduction of Oxaliplatin-based Drug Combinations for Colorectal Cancer
Favorite
T-094
Cellular and Humoral Semi-mechanistic Immune Response Models of a Vaccine Candidate for Respiratory Syncytial Virus Infection
Favorite
M-093
Challenges in curating Real World Data for modeling: A Bronchopulmonary Dysplasia case study
Favorite
W-091
Characterization of the Effect of Biofilm Formation on the Antimicrobial Activity of Tigecycline against M. abscessus using a Hollow Fiber Infection Model and Pharmacokinetic/Pharmacodynamic Modeling
Favorite
W-079
Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy
Favorite
W-045
Clinical Trial Simulation to Assess Sample Size and Power For Detecting Differences in Pharmacokinetic Exposure Metrics
Favorite
M-009
Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
Favorite
W-109
Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers
Favorite
W-064
Comparative evaluation of different vancomycin population pharmacokinetic models to predict Bayesian-estimated vancomycin AUC in Korean patients
Favorite
W-106
Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach
Favorite
T-022
Comparing the Efficacy of Various Insulin Types: A Pharmacokinetic and Pharmacodynamic Modeling Study in Healthy Volunteers
Favorite
W-080
Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data
Favorite
W-087
Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer
Favorite
T-108
Comparison of NONMEM and AI-Based Approaches for Population Pharmacokinetic Simulations to Support Model-Informed Drug Development
Favorite
T-031
Comparison of Sensitivity Analysis Methods in the Context of a QSP Model for Gout
Favorite
T-107
Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development
Favorite
W-070
Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors
Favorite
W-055
Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses
Favorite
W-114
Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all
Favorite
M-012
Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
Favorite
W-099
Constructing a virtual control arm and evaluating operating characteristics using TGI metrics to support go/no-go decisions for single-arm Phase Ib/II combination studies
Favorite
T-023
Cost-effectiveness of paliperidone palmitate long-acting injectables for the treatment of schizophrenic patients: a joint pharmacometric/pharmacoeconomic approach
Favorite
M-005
Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results
Favorite
M-127
Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments
Favorite
M-111
Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context
Favorite
D
W-011
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections
Favorite
M-065
Decoding Mean Viral Load in RSV Human Challenge Studies
Favorite
T-092
Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology
Favorite
W-139
Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose
Favorite
M-003
Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis
Favorite
M-031
Development and application of a mechanistic model for Alzheimer’s Disease
Favorite
M-046
Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment
Favorite
W-028
Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population
Favorite
W-038
Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer
Favorite
T-119
Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients
Favorite
W-101
Development of a Population PK model for an inhaled drug
Favorite
M-013
Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.
Favorite
M-080
Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV
Favorite
T-086
Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics
Favorite
W-053
Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution
Favorite
W-004
Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
Favorite
T-009
Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Favorite
T-130
Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients
Favorite
M-001
Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis
Favorite
W-141
Disease progression modeling of myositis from real-world data
Favorite
M-049
Disease Progression Modeling of Stargardt’s disease
Favorite
M-020
Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy
Favorite
W-068
Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation
Favorite
W-002
Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing’s Family Tumor Xenograft
Favorite
W-122
Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
Favorite
E
W-043
Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy
Favorite
W-015
Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model
Favorite
W-078
Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy
Favorite
W-054
Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer
Favorite
T-075
Enhancing Parameter Estimation Process for Pharmacokinetic-Pharmacodynamic Models with Meta-heuristic Optimization Approaches
Favorite
M-142
Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988
Favorite
M-023
Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach
Favorite
M-103
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM
Favorite
W-037
Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics
Favorite
M-112
Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods
Favorite
M-104
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model
Favorite
W-118
Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations
Favorite
M-125
Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach
Favorite
W-069
Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis
Favorite
M-041
Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study
Favorite
W-084
Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)
Favorite
M-074
Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Favorite
T-058
Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients
Favorite
W-074
Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Favorite
W-049
Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Favorite
M-050
Exposure-Response Analysis of Cenobamate
Favorite
T-037
Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC
Favorite
T-072
Exposure–Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Favorite
W-040
Extracting Lab Value Reference Ranges from Neonatal Real-World Data in OMOP Format
Favorite
W-065
Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation
Favorite
F
W-059
Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP model
Favorite
T-091
Fast Stepwise Selection Methods for Efficient Covariate Model Development in Population Data Analysis
Favorite
T-047
FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Favorite
W-125
Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel
Favorite
W-129
Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population
Favorite
M-091
Fully Bayesian Covariate Selection in Population Pharmacokinetics and Pharmacodynamics Models Using Regularized Horseshoe Priors
Favorite
G
W-067
Gauss-Hermite cohort population estimation of dexamethasone pharmacokinetic parameters in pregnant women using blood samples collected at birth
Favorite
T-105
Generating data-driven insights from the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Towards establishing a QSP model of Alzheimer’s disease
Favorite
W-136
Gompertz Cure Rate Survival Models with Stan and Brms
Favorite
H
M-108
How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches
Favorite
T-040
How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition Using Open-Source Julia Tools
Favorite
W-052
Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans
Favorite
T-057
Hybrid Population PK-Machine Learning Model Approach to Predict Infliximab Concentrations in Pediatric Patients with Crohn's Disease
Favorite
I
T-035
Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
Favorite
M-043
Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis
Favorite
M-055
Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis
Favorite
W-137
Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Favorite
M-060
Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia
Favorite
T-061
Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis
Favorite
T-132
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials
Favorite
W-092
Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models for Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery
Favorite
W-108
Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
Favorite
W-020
In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
Favorite
W-041
Inferring HIV rebound timing from a noisy biomarker
Favorite
W-105
Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models
Favorite
T-006
Inhibitory Potential of Cannabidiol on Major CYP450s Enzymes: Insights from Physiological-based Pharmacokinetic Modeling
Favorite
T-027
Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics
Favorite
T-089
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
Favorite
M-092
Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids
Favorite
W-017
Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest
Favorite
T-096
Integrating Motor Function Scores of Spinal Muscular Atrophy in a Quantitative Systems Pharmacology Model of Neurofilament
Favorite
T-134
Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population
Favorite
M-016
Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications
Favorite
M-082
Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Favorite
W-093
Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation
Favorite
T-030
Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation
Favorite
W-076
Interactive Pharmacometric Simulations and Model Exploration with e-Campsis
Favorite
M-015
Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain
Favorite
W-048
Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366
Favorite
J
T-121
Joint bi-directional PK-ADA population modelling in immuno-oncology
Favorite
K
M-037
K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Favorite
M-038
K-PD Modeling of Plozasiran - Mixed Hyperlipidemia
Favorite
L
M-007
Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
Favorite
M-075
Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Favorite
W-003
Leveraging Machine Learning and Real-World Data: Time-to-Event Analysis of COVID-19 Patients Using Electronic Health Records
Favorite
W-115
Leveraging PBPK modeling to advance spironolactone complex disposition knowledge
Favorite
W-001
Leveraging quantitative systems pharmacology (QSP) modeling to understand effects of corticosteroids on immune cells and cytokine release following administration of SC Epcoritamab
Favorite
W-021
Local TMDD of large molecules in tissue interstitial space
Favorite
W-032
Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.
Favorite
M-139
Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma
Favorite
T-014
Longitudinal Population Pharmacokinetic/Pharmacodynamic Modeling of Continuous Efficacy Endpoint and Biomarker for a Novel Compound
Favorite
W-133
Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models
Favorite
M
W-071
Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
Favorite
W-102
Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model
Favorite
M-004
MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.
Favorite
M-071
Mechanistic mathematical model of emicizumab
Favorite
T-051
Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases
Favorite
W-107
Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
Favorite
W-131
Mechanistic modeling to inform T cell engager development for low copy targets
Favorite
T-137
Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients
Favorite
W-047
Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design
Favorite
M-024
Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.
Favorite
T-025
Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species
Favorite
M-076
Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)
Favorite
M-044
MIDD Platform of VZV Vaccine Immunogenicity and Efficacy
Favorite
M-048
mipdtrial: an open-source R package for simulating model-informed precision dosing trials
Favorite
T-045
Mixed effect state space model application for data driven pharmacometrics modeling
Favorite
M-070
Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose
Favorite
M-087
Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Favorite
T-097
Model Predictive Control Regulates Blood Pressure During Simulated Kidney Replacement Therapy
Favorite
T-109
Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders
Favorite
T-141
Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
Favorite
W-051
Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations
Favorite
W-014
Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients
Favorite
W-083
Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Favorite
M-027
Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
Favorite
M-042
Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection
Favorite
W-121
Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function
Favorite
T-053
Modeling and inter-species scaling of plasma DHO as a biomarker to inform first-in-human dose selection for a novel DHODH inhibitor
Favorite
M-088
Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics
Favorite
W-104
Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli
Favorite
W-089
Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach
Favorite
T-138
Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials
Favorite
T-085
Modeling progression and treatment of mCRPC using the Thales QSP software platform
Favorite
W-010
Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents
Favorite
T-140
Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy
Favorite
T-095
Modeling the Role of Organ Crosstalk and Cellular Adaptation in Multiple Organ Dysfunction Syndrome
Favorite
T-052
Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study
Favorite
T-123
Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections
Favorite
N
M-140
Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
Favorite
T-032
NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation
Favorite
W-018
Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials
Favorite
M-040
Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation
Favorite
O
M-113
Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials
Favorite
W-023
Optimized Noncompartmental Half-Life Estimation with Tobit Regression
Favorite
T-082
Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea
Favorite
M-066
Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
Favorite
W-057
Optimizing Drug Development: Assessing Small Language Models for Efficient Drug-Drug Interaction Data Extraction
Favorite
M-122
Overcome the Challenges of NONMEM PopPK Dataset for Late Stage Daily Dose Study
Favorite
P
W-034
Parallel Tempering for Generation of Virtual Patients and Virtual Populations
Favorite
M-118
Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
Favorite
W-013
Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration
Favorite
M-085
PBPK-mQSP Model Analysis of KHK4951, an Eye Drop Formulation of Tivozanib, a Potent and Selective VEGF Receptor Inhibitor
Favorite
M-058
Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection of S-001, a Novel mRNA-based Therapy for Pancreatic Cancer
Favorite
T-064
Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors
Favorite
W-140
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
Favorite
W-111
Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling
Favorite
M-036
Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic
Favorite
W-100
Pharmacometrics-Based Evaluation of Fixed versus Weight-Based Dosing Strategies for Approved Antibody Drug Conjugates (ADC)
Favorite
W-135
PharmaInsight Explorer: Empowering EDA in Clinical Pharmacology and Safety Science
Favorite
W-019
Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
Favorite
W-095
Physiologically Based Pharmacokinetic (PBPK) modeling of hepatic impairment using PK-Sim
Favorite
M-059
Physiologically based pharmacokinetic (PBPK) modeling of methotrexate in cerebrospinal fluid in humans
Favorite
W-090
Physiologically Based Pharmacokinetic Model of Vedolizumab in Adult Patients with Inflammatory Bowel Disease
Favorite
W-066
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF PIOGLITAZONE: EVALUATING THE EFFECT OF THE CYTOCHROME P450 2C8*2 SINGLE NUCLEOTIDE POLYMORPHISM
Favorite
M-131
Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats
Favorite
W-029
Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
Favorite
W-130
Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus® to Predict Hepatic Concentrations
Favorite
M-124
Physiologically-based pharmacokinetic modeling approach to support eliglustat development for pediatric patients with Gaucher disease
Favorite
M-107
Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials
Favorite
M-035
PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody
Favorite
W-110
PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis
Favorite
M-053
PKPD modeling and simulation of an inhaled antibiotic targeting Gram-negative bacteria, using a bacteriophage-derived endolysin.
Favorite
T-142
PK-PD modeling of doxycycline, azithromycin, and their combination in treating severe scrub typhus using a general pharmacodynamic interaction (GPDI) model.
Favorite
M-078
PKPD Modeling of PROTACs
Favorite
T-133
Placebo Response Model for Alopecia Areata: A Model-based Meta-analysis of Randomized Controlled Trials
Favorite
W-088
pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling
Favorite
W-117
PMXModelStructuR: A Tool for Pharmacometrics Model Visualization in R
Favorite
T-028
Pooled population PK of alpelisib in patients with PIK3CA-related overgrowth spectrum and breast cancer
Favorite
T-012
popPK & ER analysis of amivantamab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure
Favorite
M-138
Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Favorite
W-044
Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Favorite
M-141
Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration
Favorite
M-086
Population Pharmacokinetic (Pop PK) Modeling of Nirmatrelvir/Ritonavir in Severe Renal Impaired Participants with COVID-19 either on or not on Hemodialysis
Favorite
W-027
Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants
Favorite
M-119
Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Favorite
W-025
Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers
Favorite
W-123
Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients
Favorite
M-077
Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis
Favorite
M-128
Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease
Favorite
W-082
Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer
Favorite
T-118
Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
Favorite
W-113
Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer
Favorite
M-115
Population Pharmacokinetic and Exposure-Response Analyses of Tasurgratinib in Subjects with Unresectable Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Gene Fusion
Favorite
M-081
Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea
Favorite
W-046
Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Favorite
W-026
Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers
Favorite
W-127
Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.
Favorite
W-050
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction
Favorite
T-059
Population Pharmacokinetic Approach to Evaluate Current Recommended Dose of Tacrolimus on Korean Pediatric Liver Transplant Patients
Favorite
M-018
Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis
Favorite
M-095
Population Pharmacokinetic Modeling Informed the Dose of GDC-8264 for a Phase 1b Study in Participants with Acute Graft-Versus-Host Disease
Favorite
T-098
Population pharmacokinetic modeling of Binimetinib in Healthy Volunteers and Participants with BRAF V600-mutant or NRAS-mutant Solid Tumors
Favorite
W-042
Population Pharmacokinetic Modeling of Hydroxyurea in Plasma and Breast Milk in Lactating Women
Favorite
W-132
Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
Favorite
M-034
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
Favorite
M-098
Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis
Favorite
W-075
Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics
Favorite
W-094
Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
Favorite
M-063
Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction
Favorite
T-076
Population Pharmacokinetic-Pharmacodynamic Modeling for Triapine to Optimize Dosing Regimen
Favorite
M-096
Population pharmacokinetics analysis of DA-8010, a novel anti-muscarinic agent
Favorite
T-139
Population Pharmacokinetics and Exposure-response Analyses of Amivantamab Administered in Combination with Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Favorite
W-142
Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC
Favorite
M-102
Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients
Favorite
M-121
Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug
Favorite
M-132
Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen
Favorite
W-128
Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)
Favorite
M-084
Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged <12 Months
Favorite
W-126
Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents
Favorite
T-087
Population pharmacokinetics of cefepime in critically ill children and young adults
Favorite
T-007
Population Pharmacokinetics of Enoxaparin in Neonates and Infants
Favorite
M-047
Population Pharmacokinetics of Nivolumab in Patients with Newly Diagnosed or Relapsed/Refractory Classical Hodgkin Lymphoma
Favorite
W-056
Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
Favorite
W-119
Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias
Favorite
W-030
Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies
Favorite
T-055
Population PK model on preclinical data for optimization of further clinical trial designs in oncology
Favorite
W-036
Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
Favorite
T-135
Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example
Favorite
M-054
Preclinical data exposures underpredict clinical physiologically active doses for bispecific TCEs in solid tumors indications; are there better metrics? - insights from a small mechanistic MBMA
Favorite
T-093
Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment
Favorite
W-097
Predicting pharmacokinetic profile of small molecule drugs based on chemical structure using machine learning.
Favorite
W-086
Prediction of progression free survival using tumor growth inhibition models: Effect of model uncertainty, inter-individual variability and observational noise on prediction accuracy
Favorite
W-103
Prediction of the Biological Effect of PEG-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach
Favorite
W-039
Predictive Pharmacokinetic Analysis of Novel PLCG2 Inhibitors Using GastroPlus and ADMET Predictor
Favorite
M-019
Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes
Favorite
Q
T-113
QSP model trained on preclinical data informs clinical dose selection for a T-cell engaging bispecific antibody for solid tumor indications
Favorite
W-058
QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease
Favorite
T-126
Quantification of uncertainty in human dose predictions
Favorite
W-081
Quantifying dengue natural immunity and probability of disease using serum antibody titers
Favorite
M-010
Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216
Favorite
T-008
Quantitative Systems Pharmacology (QSP) model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus
Favorite
W-060
Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Favorite
T-077
Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients with DLBCL
Favorite
W-061
Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Favorite
W-120
Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients
Favorite
W-096
Quantitative Systems Pharmacology of T-cell Engagers and Cytokine Release
Favorite
M-120
Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing
Favorite
R
W-124
Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
Favorite
T-102
Redefining Multidrug Resistance Quantitatively using Live Cell Functional Data
Favorite
W-012
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
Favorite
T-002
Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model
Favorite
W-016
Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias
Favorite
T-074
Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach
Favorite
W-098
Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma
Favorite
S
T-114
SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets
Favorite
W-031
Scientific Project Management (SPM) to Enhance Model-Informed Drug Development
Favorite
M-117
Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment
Favorite
W-062
SEMI-PHYSIOLOGIC POPULATION PHARMACOKINETIC MODEL TO EVALUATE THE EFFECT OF HEPATIC-UPTAKE TRANSPORTER GENE SLC22A1 POLYMORPHISM ON PHARMACOKINETICS OF PROGUANIL AND ITS METABOLITE, CYCLOGUANIL
Favorite
T-021
Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients
Favorite
M-105
Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study
Favorite
T-019
Simulate modified Nonmem models using NMsim
Favorite
T-106
Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data
Favorite
W-007
Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve
Favorite
T-110
Simulation of Trial Predictions with Model Uncertainty using NMsim
Favorite
W-022
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
Favorite
W-116
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Favorite
W-024
Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.
Favorite
M-067
Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies
Favorite
M-123
Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection
Favorite
M-062
Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
Favorite
T-127
Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton’s tyrosine kinase inhibitor case study
Favorite
T-039
Symbolic PBPK-PDE Modeling Using Open-Source Julia Tools
Favorite
W-035
Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma
Favorite
T
T-054
The effect of CYP2B6 genotype on the clearance and autoinduction of efavirenz in healthy subjects and the subsequent impact on efavirenz exposure.
Favorite
M-051
The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM
Favorite
W-085
The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach
Favorite
T-038
The PK-PD model of dexamethasone for fetal lung maturation and developmental neurotoxicity: A dose optimization study
Favorite
W-008
The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships
Favorite
M-021
Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer
Favorite
M-022
Towards A QSP Platform To Support Drug Development In Hematological Cancers
Favorite
T-034
Translational modeling identifies synergistic combinations of anti-microRNA-155 with standard-of-care drugs in non-small-cell lung cancer
Favorite
T-124
Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
Favorite
U
T-136
Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Favorite
W-072
Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
Favorite
W-112
Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Favorite
T-042
Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease
Favorite
M-133
Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Favorite
W-005
Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
Favorite
V
M-114
Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients
Favorite
M-045
Visual predictive check of longitudinal models and dropout
Favorite
W
T-065
Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model
Favorite
T-090
Whole-body Two-pore PBPK Model to Investigate the Disposition of Immunoglobulin M (IgM) in Mice
Favorite
X
W-073
xplorer: a Flexible Shiny App for Data Visualization, Exploration and Quality Assurance
Favorite
Z
T-020
Zolpidemsim: A Web-Application for Simulating Pharmacokinetics of Zolpidem
Favorite
